^
    Back
    Association details:
    Biomarker:ATM mutation
    Cancer:Squamous Cell Carcinoma of Head and Neck
    Drug:Imfinzi (durvalumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ASCO 2020
    Title:

    Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.

    Published date:
    05/13/2020
    Excerpt:
    Pts with mutations in ATM (5%), a DNA damage repair gene, also trended with prolonged OS.
    DOI:
    10.1200/JCO.2020.38.15_suppl.6548